Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG156

—

48c37d8f-3d2e-5a4e-a1a1-4396fe0fae88

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • E2F_TARGETS+0.515
  • MYC_TARGETS_V2+0.500
  • G2M_CHECKPOINT+0.478
  • ANGIOGENESIS+0.423
  • PANCREAS_BETA_CELLS+0.362
  • UNFOLDED_PROTEIN_RESPONSE+0.320
  • MTORC1_SIGNALING+0.302
  • SPERMATOGENESIS+0.284
  • MYC_TARGETS_V1+0.278
  • GLYCOLYSIS+0.263

Top 10 suppressed

  • TGF_BETA_SIGNALING-0.312
  • BILE_ACID_METABOLISM-0.302
  • UV_RESPONSE_DN-0.300
  • PEROXISOME-0.279
  • INTERFERON_ALPHA_RESPONSE-0.267
  • CHOLESTEROL_HOMEOSTASIS-0.257
  • HEME_METABOLISM-0.250
  • ANDROGEN_RESPONSE-0.248
  • ADIPOGENESIS-0.197
  • WNT_BETA_CATENIN_SIGNALING-0.182

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1MNG155
mng-umap@100
——0.805
2MNG732
mng-umap@100
——0.796
3MNG192
mng-umap@100
——0.781
4SRR8518152
breast-umap@18
—E0.776
5MNG883
mng-umap@100
——0.772
6TCGA-22-1012-01A-01R-0692-07
lung-landscapes@6
—cohortSQ20.763
7MNG1082
mng-umap@100
——0.746
8SRR975564
colon-landscapes@1
——0.739
9SJEPD032407_D2.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.725
103e94d9d5-8c59-4366-babb-193bdc57d661
melanoma-umap@29
——0.720

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 25 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
E2F_TARGETS0.515Inavolisib— uncovered
MYC_TARGETS_V20.500Idelalisib— uncovered
G2M_CHECKPOINT0.478Inavolisib— uncovered
ANGIOGENESIS0.423Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.362Cobimetinib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.320Idelalisib— uncovered
MTORC1_SIGNALING0.302Inavolisib— uncovered
SPERMATOGENESIS0.284Inavolisib— uncovered
MYC_TARGETS_V10.278Inavolisib— uncovered
GLYCOLYSIS0.263Inavolisib— uncovered
HYPOXIA0.228Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.161Inavolisib— uncovered
MITOTIC_SPINDLE0.118Inavolisib— uncovered
APICAL_SURFACE0.108Temsirolimus— uncovered
KRAS_SIGNALING_DN0.107Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.098Idelalisib— uncovered
DNA_REPAIR0.092Idelalisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.091Inavolisib— uncovered
KRAS_SIGNALING_UP0.072Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.034Idelalisib— uncovered